Objective To investigate the mechanism of Xiaozheng Huoluo prescription (XZHLF) in the prevention and treatment of liver fibrosis based on network pharmacology.Methods TCMSP database, Chemistry Database, ETCM database, chemical source network database, ChemSrc database, and PubChem database were searched and a literature review was performed to collect the chemical components of each traditional Chinese medicine of XZHLF, Swiss ADME database was used to screen out the active components of each traditional Chinese medicine of XZHLF, and Swiss Target Prediction database was used to predict the targets of these active components; GeneCards and OMIN databases were used to collect the disease targets of liver fibrosis, and Venn diagrams were used to obtain the potential targets of XZHLF in the prevention and treatment of liver fibrosis. Cytoscape 3.7.1 software was used to establish a "drug-active component" network for XZHLF and an "active component-potential target" network for XZHLF in the prevention and treatment of liver fibrosis. Metascape database was used to perform GO and KEGG enrichment analysis of potential targets, and bubble charts were plotted for the top 20 pathways with the highest number of enriched genes. The MAPK signaling pathway among the top 20 KEGG pathways was analyzed to plot an "active component-potential target-pathway" network. Healthy Sprague-Dawley rats were randomly divided into blank control group (K group), model group (M group), colchicine-positive control group (Y group), high-dose XZHLF group (G group), middle-dose XZHLF group (Z Group), and low-dose XZHLF group (D group), and a rat model of liver fibrosis was established by CCl4; the drug was administered simultaneously for 8 weeks. Western blot was used to measure the protein expression of ERK5, p-ERK5, MEK5, and MEKK3 in liver tissue. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups.Results A total of 110 active components were screened out from XZHLF and they acted on 923 targets, which were mapped to 6823 disease targets of liver fibrosis to obtain 647 potential targets. XZHLF might act on multiple protein targets such as EGFR, AKT1, IKBKB, MAPK8, and PDGFRB through the pathways including the MAPK signaling pathway and the biological processes including the regulation of MAPK cascade, thereby playing a role in the prevention and treatment of liver fibrosis. The M group had significant increases in the protein levels of ERK5, p-ERK5, MEK5, and MEKK3 in liver tissue compared with the K, Y, G, Z, and D groups (all P < 0.05), and the K group had significant reductions in the protein levels of ERK5, p-ERK5, MEK5, and MEKK3 in liver tissue compared with the Y, G, Z, and D groups (all P < 0.05).Conclusion Based on the method of network pharmacology, it is predicted that XZHLF may prevent and treat liver fibrosis via the MAPK signaling pathway, and it is verified through experiments that XZHLF prevents and treats liver fibrosis via the ERK5 pathway in the MAPK signaling pathway family. The high-dose XZHLF group shows the most obvious anti-liver fibrosis effect.
流式细胞术检测慢病毒感染5天后的BEL-7404细胞周期,沉默组的G1期细胞比例显著高于对照组(49.9%±0.8% vs 44.0%±0.9%,t=8.96,P<0.001),G2/M期细胞比例显著低于对照组(15.9%±0.2% vs 17.9%±0.7%,t=9.13,P<0.001),S期细胞比例显著低于对照组(34.2%±0.6% vs 38.1%±0.5%,t=6.91,P<0.001)(图6)。
图
6
不同处理组BEL-7404细胞周期情况
Figure
6.
Cell cycle of BEL-7404 cells in different treatment groups
EME1对于哺乳动物细胞中 DNA 代谢的各个方面都很重要,Guo等[10]研究发现EME1与胃癌细胞AGS和MGC-803的增殖及侵袭能力密切相关,沉默EME1基因表达可通过抑制蛋白激酶B活化,降低糖原合酶激酶-3β、细胞周期蛋白D1,从而抑制癌细胞增殖和侵袭,促进细胞凋亡。基于中国广西人群的研究[11]发现EME1的Glu69Asp错义多态性与肝癌风险增加显著相关。EME1的另一外显子Ile350Thr变异会提高乳腺癌的易感性[12]。
WYNN TA, RAMALINGAM TR. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease[J]. Nat Med, 2012, 18(7): 1028-1040. DOI: 10.1038/nm.2807
[3]
SEKI E, BRENNER DA. Recent advancement of molecular mechanisms of liver fibrosis[J]. J Hepatobiliary Pancreat Sci, 2015, 22(7): 512-518. DOI: 10.1002/jhbp.245
[4]
TANG CF. Experimental and clinical study on Xiaozheng Huoluo Fang in prevention and treatment of liver arthralgia[D]. Changchun: Changchun University of Chinese Medicine, 2016. (in Chinese)
唐成芳. 消癥活络方防治肝痹的实验与临床研究[D]. 长春: 长春中医药大学, 2016.
[5]
DAI DX, PAN Z, TANG CF, et al. Effect of Xiaozheng Huoluo Fang on the expression of α-SMA and TGF-β1 in liver tissue of rats with hepatic fibrosis[J]. Jilin J Chin Med, 2017, 37(2): 162-166. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJL201702016.htm
LI S, ZHANG B. Traditional Chinese medicine network pharmacology: Theory, methodology and application[J]. Chin J Nat Med, 2013, 11(2): 110-120. http://europepmc.org/abstract/MED/23787177
[7]
JIN JJ, ZHONG M, YU SM, et al. Therapeutic effect of water extract of chuanposhi on hepatic fibrosis induced by carbon tetrachloride in rats[J]. Chin J Experi Tradi Med Form, 2012, 18(22): 258-262. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201222075.htm
NISHIMOTO S, NISHIDA E. MAPK signalling: ERK5 versus ERK1/2[J]. EMBO Rep, 2006, 7(8): 782-786. DOI: 10.1038/sj.embor.7400755
[13]
CHAO TH, HAYASHI M, TAPPING RI, et al. MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway[J]. J Biol Chem, 1999, 274(51): 36035-36038. DOI: 10.1074/jbc.274.51.36035
[14]
SUN W, KESAVAN K, SCHAEFER BC, et al. MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway[J]. J Biol Chem, 2001, 276(7): 5093-5100. DOI: 10.1074/jbc.M003719200
[15]
ENGLISH JM, VANDERBILT CA, XU S, et al. Isolation of MEK5 and differential expression of alternatively spliced forms[J]. J Biol Chem, 1995, 270(48): 28897-28902. DOI: 10.1074/jbc.270.48.28897
WANG Y, SU B, XIA Z. Brain-derived neurotrophic factor activates ERK5 in cortical neurons via a Rap1-MEKK2 signaling cascade[J]. J Biol Chem, 2006, 281(47): 35965-35974. DOI: 10.1074/jbc.M605503200
[18]
DORADO F, VELASCO S, ESPARÍS-OGANDO A, et al. The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation[J]. Nephrol Dial Transplant, 2008, 23(11): 3403-3411. DOI: 10.1093/ndt/gfn333
[19]
RAMSAY AK, MCCRACKEN SR, SOOFI M, et al. ERK5 signalling in prostate cancer promotes an invasive phenotype[J]. Br J Cancer, 2011, 104(4): 664-672. DOI: 10.1038/sj.bjc.6606062
[20]
URUSHIHARA M, TAKAMATSU M, SHIMIZU M, et al. ERK5 activation enhances mesangial cell viability and collagen matrix accumulation in rat progressive glomerulonephritis[J]. Am J Physiol Renal Physiol, 2010, 298(1): F167-F176. DOI: 10.1152/ajprenal.00124.2009
PU Zaichun, JIA Ping, LIU Juan, et al. Risk prediction models for pancreatic fistula after pancreaticoduodenectomy: A systematic review and a Meta-analysis[J]. J Clin Hepatol, 2024, 40(11): 2266-2276. DOI: 10.12449/JCH241121.
PU Zaichun, JIA Ping, LIU Juan, et al. Risk prediction models for pancreatic fistula after pancreaticoduodenectomy: A systematic review and a Meta-analysis[J]. J Clin Hepatol, 2024, 40(11): 2266-2276. DOI: 10.12449/JCH241121.